Branched-chain amino acids ameliorate fibrosis and suppress tumor growth in a rat model of hepatocellular carcinoma with liver cirrhosis

PLoS ONE

Volumn 8, Issue 11, 2013, Pages

  Cha, Jung Hoon ^a   Bae, Si Hyun ^a   Kim, Hye Lim ^a   Park, Na Ri ^a   Choi, Eun Suk ^a   Jung, Eun Sun ^a   Choi, Jong Young ^a   Yoon, Seung Kew ^a  

^a The Catholic University of Korea   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ALPHA SMOOTH MUSCLE ACTIN; AMMONIA; ANGIOPOIETIN RECEPTOR; ANTIFIBROTIC AGENT; ANTINEOPLASTIC AGENT; BETA CATENIN; BILIRUBIN; BIOLOGICAL MARKER; BRANCHED CHAIN AMINO ACID; CASEIN; CASPASE 3; COLLAGEN TYPE 1; COLLAGEN TYPE 1 ALPHA2; COLLAGEN TYPE 3; COLLAGEN TYPE 3 ALPHA1; CYCLINE; DIETHYLNITROSAMINE; HYPOXIA INDUCIBLE FACTOR 1ALPHA; INSULIN; LEUCYLISOLEUCYLVALINE; MESSENGER RNA; MITOGEN ACTIVATED PROTEIN KINASE P38; PROTEIN MCL 1; SMAD4 PROTEIN; TISSUE INHIBITOR OF METALLOPROTEINASE 1; TISSUE INHIBITOR OF METALLOPROTEINASE 2; TRANSFORMING GROWTH FACTOR BETA1; UNCLASSIFIED DRUG; UNINDEXED DRUG; VASCULOTROPIN;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; AMMONIA BLOOD LEVEL; ANGIOGENESIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIFIBROTIC ACTIVITY; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; BILIRUBIN BLOOD LEVEL; CANCER INHIBITION; CANCER PREVENTION; CONTROLLED STUDY; DIET SUPPLEMENTATION; DOWN REGULATION; DRUG ACTIVITY; DYSPLASIA; GENE EXPRESSION; HISTOPATHOLOGY; INSULIN RESISTANCE; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LIVER FIBROSIS; LIVER NODULE; MALE; NONHUMAN; PROTEIN CLEAVAGE; PROTEIN EXPRESSION; RAT; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SCORING SYSTEM; TUMOR VASCULARIZATION; WESTERN BLOTTING; ANIMAL; CARCINOGENESIS; CARCINOMA, HEPATOCELLULAR; CHEMICALLY INDUCED; DRUG EFFECTS; LIVER CIRRHOSIS, EXPERIMENTAL; LIVER NEOPLASMS, EXPERIMENTAL; NEOVASCULARIZATION, PATHOLOGIC; ORAL DRUG ADMINISTRATION; PATHOLOGY; SPRAGUE DAWLEY RAT; TUMOR VOLUME;

ADMINISTRATION, ORAL; AMINO ACIDS, BRANCHED-CHAIN; ANIMALS; ANTICARCINOGENIC AGENTS; CARCINOGENESIS; CARCINOMA, HEPATOCELLULAR; DIETHYLNITROSAMINE; LIVER CIRRHOSIS, EXPERIMENTAL; LIVER NEOPLASMS, EXPERIMENTAL; MALE; NEOVASCULARIZATION, PATHOLOGIC; RATS; RATS, SPRAGUE-DAWLEY; TUMOR BURDEN;

EID: 84891380777     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0077899     Document Type: Article

References (42)

1. Block TM, Mehta AS, Fimmel CJ, Jordan R (2003) Molecular viral oncology of hepatocellular carcinoma. Oncogene 22: 5093-5107.
2. El-Serag HB, Rudolph KL (2007) Hepatocellular carcinoma: epidemiology and molecular carcinogenesis. Gastroenterology 132: 2557-2576.
3. Donadon V, Balbi M, Casarin P, Vario A, Alberti A (2008) Association between hepatocellular carcinoma and type 2 diabetes mellitus in Italy: potential role of insulin. World J Gastroenterol 14: 5695-5700.
4. El-Serag HB, Hampel H, Javadi F (2006) The association between diabetes and hepatocellular carcinoma: a systematic review of epidemiologic evidence. Clin Gastroenterol Hepatol 4: 369-380.
5. Lai MS, Hsieh MS, Chiu YH, Chen TH (2006) Type 2 diabetes and hepatocellular carcinoma: A cohort study in high prevalence area of hepatitis virus infection. Hepatology 43: 1295-1302.
6. Nair S, Mason A, Eason J, Loss G, Perrillo RP (2002) Is obesity an independent risk factor for hepatocellular carcinoma in cirrhosis? Hepatology 36: 150-155.
7. Schiel R, Beltschikow W, Steiner T, Stein G (2006) Diabetes, insulin, and risk of cancer. Methods Find Exp Clin Pharmacol 28: 169-175.
8. Kawaguchi T, Izumi N, Charlton MR, Sata M (2011) Branched-chain amino acids as pharmacological nutrients in chronic liver disease. Hepatology 54: 1063-1070.
9. Moriwaki H, Miwa Y, Tajika M, Kato M, Fukushima H, et al. (2004) Branched-chain amino acids as a protein- and energy-source in liver cirrhosis. Biochem Biophys Res Commun 313: 405-409.
10. Marchesini G, Bianchi G, Merli M, Amodio P, Panella C, et al. (2003) Nutritional supplementation with branched-chain amino acids in advanced cirrhosis: a double-blind, randomized trial. Gastroenterology 124: 1792-1801.
11. Muto Y, Sato S, Watanabe A, Moriwaki H, Suzuki K, et al. (2005) Effects of oral branched-chain amino acid granules on event-free survival in patients with liver cirrhosis. Clin Gastroenterol Hepatol 3: 705-713.
12. Muto Y, Sato S, Watanabe A, Moriwaki H, Suzuki K, et al. (2006) Overweight and obesity increase the risk for liver cancer in patients with liver cirrhosis and long-term oral supplementation with branched-chain amino acid granules inhibits liver carcinogenesis in heavier patients with liver cirrhosis. Hepatol Res 35: 204-214.
13. Kawaguchi T, Nagao Y, Matsuoka H, Ide T, Sata M (2008) Branched-chain amino acid-enriched supplementation improves insulin resistance in patients with chronic liver disease. Int J Mol Med 22: 105-112.
14. Kawaguchi T, Taniguchi E, Itou M, Sumie S, Oriishi T, et al. (2007) Branchedchain amino acids improve insulin resistance in patients with hepatitis C virusrelated liver disease: report of two cases. Liver Int 27: 1287-1292.
15. Iwasa J, Shimizu M, Shiraki M, Shirakami Y, Sakai H, et al. (2010) Dietary supplementation with branched-chain amino acids suppresses diethylnitrosa-mine- induced liver tumorigenesis in obese and diabetic C57BL/KsJ-db/db mice. Cancer Sci 101: 460-467.
16. Yoshiji H, Noguchi R, Kitade M, Kaji K, Ikenaka Y, et al. (2009) Branchedchain amino acids suppress insulin-resistance-based hepatocarcinogenesis in obese diabetic rats. J Gastroenterol 44: 483-491.
17. Czaja MJ, Weiner FR, Flanders KC, Giambrone MA, Wind R, et al. (1989) In vitro and in vivo association of transforming growth factor-beta 1 with hepatic fibrosis. J Cell Biol 108: 2477-2482.
18. Raghow R, Postlethwaite AE, Keski-Oja J, Moses HL, Kang AH (1987) Transforming growth factor-beta increases steady state levels of type I procollagen and fibronectin messenger RNAs posttranscriptionally in cultured human dermal fibroblasts. J Clin Invest 79: 1285-1288.
19. Nie QH, Duan GR, Luo XD, Xie YM, Luo H, et al. (2004) Expression of TIMP-1 and TIMP-2 in rats with hepatic fibrosis. World J Gastroenterol 10: 86- 90.
20. Feng XH, Derynck R (2005) Specificity and versatility in tgf-beta signaling through Smads. Annu Rev Cell Dev Biol 21: 659-693.
21. Giavazzi R, Taraboletti G (1999) Angiogenesis and angiogenesis inhibitors in cancer. Forum (Genova) 9: 261-272.
22. Risau W (1997) Mechanisms of angiogenesis. Nature 386: 671-674.
23. Folkman J (1990) What is the evidence that tumors are angiogenesis dependent? J Natl Cancer Inst 82: 4-6.
24. Holash J, Maisonpierre PC, Compton D, Boland P, Alexander CR, et al. (1999) Vessel cooption, regression, and growth in tumors mediated by angiopoietins and VEGF. Science 284: 1994-1998.
25. Pugh CW, Ratcliffe PJ (2003) Regulation of angiogenesis by hypoxia: role of the HIF system. Nat Med 9: 677-684.
26. Heindryckx F, Mertens K, Charette N, Vandeghinste B, Casteleyn C, et al. (2010) Kinetics of angiogenic changes in a new mouse model for hepatocellular carcinoma. Mol Cancer 9: 219.
27. Hanahan D, Weinberg RA (2000) The hallmarks of cancer. Cell 100: 57-70.
28. Plati J, Bucur O, Khosravi-Far R (2011) Apoptotic cell signaling in cancer progression and therapy. Integr Biol (Camb) 3: 279-296.
29. Sieghart W, Losert D, Strommer S, Cejka D, Schmid K, et al. (2006) Mcl-1 overexpression in hepatocellular carcinoma: a potential target for antisense therapy. J Hepatol 44: 151-157.
30. Inoue S, Browne G, Melino G, Cohen GM (2009) Ordering of caspases in cells undergoing apoptosis by the intrinsic pathway. Cell Death Differ 16: 1053-1061.
31. Schiffer E, Housset C, Cacheux W, Wendum D, Desbois-Mouthon C, et al. (2005) Gefitinib, an EGFR inhibitor, prevents hepatocellular carcinoma development in the rat liver with cirrhosis. Hepatology 41: 307-314.
32. Shimizu M, Shirakami Y, Iwasa J, Shiraki M, Yasuda Y, et al. (2009) Supplementation with branched-chain amino acids inhibits azoxymethaneinduced colonic preneoplastic lesions in male C57BL/KsJ-db/db mice. Clin Cancer Res 15: 3068-3075.
33. Hagiwara A, Nishiyama M, Ishizaki S (2011) Branched-chain amino acids prevent insulin-induced hepatic tumor cell proliferation by inducing apoptosis through mTORC1 and mTORC2-dependent mechanisms. J Cell Physiol.
34. Park ST, Jang JW, Kim GD, Park JA, Hur W, et al. (2010) Beneficial effect of metronomic chemotherapy on tumor suppression and survival in a rat model of hepatocellular carcinoma with liver cirrhosis. Cancer Chemother Pharmacol 65: 1029-1037.
35. Butterworth RF, Giguere JF, Michaud J, Lavoie J, Layrargues GP (1987) Ammonia: key factor in the pathogenesis of hepatic encephalopathy. Neurochem Pathol 6: 1-12.
36. Holecek M (2010) Three targets of branched-chain amino acid supplementation in the treatment of liver disease. Nutrition 26: 482-490.
37. Zhou X, Thompson JR (1996) Regulation of glutamate dehydrogenase by branched-chain amino acids in skeletal muscle from rats and chicks. Int J Biochem Cell Biol 28: 787-793.
38. Verrecchia F, Mauviel A (2007) Transforming growth factor-beta and fibrosis. World J Gastroenterol 13: 3056-3062.
39. Nie QH, Cheng YQ, Xie YM, Zhou YX, Bai XG, et al. (2002) Methodologic research on TIMP-1, TIMP-2 detection as a new diagnostic index for hepatic fibrosis and its significance. World J Gastroenterol 8: 282-287.
40. Nakanishi C, Doi H, Katsura K, Satomi S (2010) Treatment with L-valine ameliorates liver fibrosis and restores thrombopoiesis in rats exposed to carbon tetrachloride. Tohoku J Exp Med 221: 151-159.
41. Murata K, Moriyama M (2007) Isoleucine, an essential amino acid, prevents liver metastases of colon cancer by antiangiogenesis. Cancer Res 67: 3263-3268.
42. Fukuda R, Hirota K, Fan F, Jung YD, Ellis LM, et al. (2002) Insulin-like growth factor 1 induces hypoxia-inducible factor 1-mediated vascular endothelial growth factor expression, which is dependent on MAP kinase and phosphatidylinositol 3-kinase signaling in colon cancer cells. J Biol Chem 277: 38205-38211.